Inventor · disambiguated record
Jens Wuerthner
Also filed as: WUERTHNER JENS
5 granted patents·13 pending applications·12 citations·filing 2016–2023
74Inventor score
Top patents by PatentIndex Score
18 records- 0187US10544223B2Combination therapy with an anti-axl antibody-drug conjugateADC THERAPEUTICS SA·Filed 2018·Granted Jan 28, 2020·5 cites·21 claims
- 0282US11596696B2Combination therapy with an anti-CD25 antibody-drug conjugateADC THERAPEUTICS SA·Filed 2018·Granted Mar 7, 2023·3 cites·13 claims
- 0378US11426467B2Dosage regimes for the administration of an anti-CD25 ADCADC THERAPEUTICS SA·Filed 2018·Granted Aug 30, 2022·1 cites·25 claims
- 0469US10966978B2Dose and regimen for HDM2-p53 interaction inhibitorsNOVARTIS AG·Filed 2017·Granted Apr 6, 2021·2 cites·20 claims
- 0569US10935540B2GDF-15 as a haematological toxicity biomarkerNOVARTIS AG·Filed 2016·Granted Mar 2, 2021·1 cites·14 claims
- 0666US2023149556A1Combination therapyADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 0765US2023039868A1Dosage regimesADC THERAPEUTICS SA·Filed 2022·Application pending·0 cites
- 0862US2021255166A1Gdf-15 as a haematological toxicity biomarkerNOVARTIS AG·Filed 2021·Application pending·0 cites
- 0957US2021247383A1Gdf-15 as a haematological toxicity biomarkerNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1056US2022031697A1Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumorsNOVARTIS AG·Filed 2021·Application pending·0 cites
- 1155US2020405879A1Combination therapyADC THERAPEUTICS SA·Filed 2018·Application pending·0 cites
- 1252US2025152725A1Combination therapy with an anti-axl antibody-pbd conjugate and nanocupsOXSONICS LTD·Filed 2023·Application pending·0 cites
- 1350US2020129637A1Combination therapy with an anti-axl antibody-drug conjugateADC THERAPEUTICS SA·Filed 2018·Application pending·0 cites
- 1450US2022111065A1Molecular adjuvantADC THERAPEUTICS SA·Filed 2019·Application pending·0 cites
- 1549US2023099010A1Combination therapyADC THERAPEUTICS SA·Filed 2020·Application pending·0 cites
- 1646US2020281925A1Dose and regimen for an hdm2-p53 interaction inhibitor in hematological tumorsNOVARTIS AG·Filed 2018·Application pending·0 cites
- 1743US2021363254A1Pharmaceutical combinationsNOVARTIS AG·Filed 2019·Application pending·0 cites
- 1840US2020129638A1Combination therapy with an anti-psma antibody-drug conjugateADC THERAPEUTICS SA·Filed 2018·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Jens Wuerthner files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →